PERRIGO PLC (Israel) Financial Indicators Patterns

We recommend you to use PERRIGO PLC fundamental analysis to find out if markets are now mispricing the firm. In other words this interface allows you to confirm available drivers of PERRIGO PLC as well as the relationship between them. We found thirty-four available financial ratios for PERRIGO PLC which can be compared to its competitors. To make sure the equity is not overpriced, please check all PERRIGO PLC fundamentals including its Gross Profit, Net Income and the relationship between Revenue and EBITDA .

Chance of Financial Distress

PERRIGO PLC has    50 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info

PERRIGO PLC Company Summary

PERRIGO PLC competes with MEDIGUS. Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland. PERRIGO PLC operates under Drug Manufacturers - Specialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 10600 people.

PERRIGO PLC Price to Sales vs Debt to Equity

PERRIGO PLC is considered to be number one stock in price to sales category among related companies. It is considered to be number one stock in debt to equity category among related companies fabricating about  0.11  of Debt to Equity per Price to Sales. The ratio of Price to Sales to Debt to Equity for PERRIGO PLC is roughly  9.36 

PERRIGO PLC Market Fundamentals

Follow Benchmarks with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
See also Your Equity Center. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.